Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1753

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Des Structure)

Chemical Structure (Des Structure)
Chemical structure diagram showing the molecular composition of desvenlafaxine, the active ingredient in the medication Desvenlafaxine 50 mg extended-release tablets by Bryant Ranch Prepack.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A pharmacokinetic chart showing geometric mean ratio (90% CI) for Desvenlafaxine across renal impairment (mild to end stage renal disease), hepatic impairment (mild to severe), and population subgroups by gender and age. The chart plots Cmax and AUC values relative to a reference, with confidence intervals displayed as horizontal error bars.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A horizontal bar chart showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic variables Cmax and AUC in the presence of the CYP3A4 inhibitor ketoconazole. The chart compares change relative to reference, with Cmax around 1.08 and AUC around 1.43.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A forest plot chart showing the geometric mean ratio (with 90% confidence intervals) of pharmacokinetic parameters (Cmax and AUC) for various drugs interacting with desvenlafaxine at different doses. The chart compares the changes in drug concentration and exposure, listing CYP2D6 substrates (Desipramine), CYP3A4 substrates (Midazolam), and dual CYP2D6 & CYP3A4 substrates (Tamoxifen and Aripiprazole), with their corresponding ratios relative to reference values plotted along the x-axis.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing the estimated proportion of patients with relapse (%) over time (days from randomization) between Desvenlafaxine Extended-Release Tablets 50 mg and placebo. The graph shows two lines: a blue solid line for Desvenlafaxine 50 mg and a red dashed line for placebo, illustrating relapse rates up to 200 days.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier curve showing the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine extended-release tablets versus placebo. The y-axis displays the percentage of patients with relapse, and the x-axis shows time up to 200 days. The plot compares relapse rates between the treatment and placebo groups, with the placebo line consistently higher.*
FDA Label Image

Label (Lbl713351753)

Label (Lbl713351753)
Label for Desvenlafaxine ER 50 mg Tablet packaged by Bryant Ranch Prepack, Burbank, CA 91504. The label includes a lot number 1523487 and storage instructions to keep the tablets at room temperature 20°-25°C (68°-77°F). It states the product is to be compared to Pristiq 50 mg Tablet from Yichang Humanwell OSD Plant, is prescription only, and has an NDC of 71335-1753-1. The package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.